New pill aims to keep deadly leukemia at bay after risky transplant
NCT ID NCT03728335
Summary
This study tests whether taking a daily pill called enasidenib can help prevent acute myeloid leukemia (AML) from coming back after a patient receives a stem cell transplant from a donor. The pill is designed to block a specific enzyme that helps cancer cells grow. The trial involves 35 patients with AML who have a particular genetic change (IDH2 mutation) and have recently undergone transplant. The main goal is to see if the treatment is safe and helps keep patients in remission longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.